The German Pharmaceutical Society (DPhG) has awarded Prof. Dr. Stefan Laufer the Carl Mannich Medal 2024. The Carl Mannich Medal is the DPhG's highest award for outstanding achievements in the field of scientific pharmacy.

Professor Laufer studied pharmacy in Regensburg. After gaining his license to practice as a pharmacist, he obtained his doctorate (Dr. rer. nat.) in Regensburg in 1989. He then went into the pharmaceutical industry and worked at Merckle Pharmaceuticals for nine years. In 1997, Laufer habilitated in pharmaceutical chemistry and was appointed private lecturer at the Johannes Gutenberg University in Mainz. In 1999, he accepted the call for a C4 professorship for pharmaceutical chemistry at the University of Tübingen (successor to Prof. Dr. Roth), which he has held ever since. 

Laufer is a pioneer in the field of kinase inhibitors and has contributed significantly to the early development of selective protein kinase inhibitors as antitumor therapeutics. In his research projects, he has also worked on numerous other targets (including COX-1/2/3, lipoxygenases, cPLA₂, transcription factors and replication proteins). An impressive number of the molecules developed by himhave made it into clinical development. 640 publications, amongst others in Nature Medicine and Lancet, 48 patents and the supervision of 114 dissertations and 4 habilitations are proof of his scientific success. 

Laufer has always been committed to the pharmaceutical sciences and was President of the German Pharmaceutical Society from 2016 to 2019. 

Prof. Dr. Ulrich Jaehde
DPhG-President

• TÜCAD2
• ICEPHA
• DPhG
• GDCH (Vorstand Fachgruppe Medizinische Chemie)
• DECHEMA (Fachgruppenbeirat Chemische Biologie)
• EU-Open Screen (Member, Cooperation Partner)
• iFIT2.0: Principle Inverstigator Excellence Cluster Proposal
• Exzellenzcluster 2180 "Image-guided and Functionally Instructed Tumor Therapies" (iFIT): PI and Member Steering Committee
• INCT Inofar (Chief Researcher)
• Journal of Medicinal Chemistry (EAB-Member)
• Structural Genomics Consortium
  • Human Janus kinase 3 (a protein tyrosine kinase, leukocyte)
  • FM-381 A Chemical Probe For JAK3
• Chemical Probes (Scientific Advisory Board)
• Inflammopharmacology (Section Editor, New Drug Developments)
• Targeting Protein kinases
• Eicosanoides in inflammation and cancer
• Anti-inflammatory drugs from natural sources
• c-a-i-r
• Macrocept
• NCT-SW TüCADD, member “erweiterter Vorstand”    NCT-SW - Standorte
• Inte:Ligand Ligandscout

• GUC (German University in Cairo)
• Academia Brasileira de Ciências